TY - JOUR
T1 - Diagnosis and Management of T2-High Asthma
AU - Coverstone, Andrea M.
AU - Seibold, Max A.
AU - Peters, Michael C.
N1 - Publisher Copyright:
© 2019
PY - 2020/2
Y1 - 2020/2
N2 - Type 2 (T2) inflammation plays a key role in the pathogenesis of asthma. IL-4, IL-5, and IL-13, along with other inflammatory mediators, lead to increased cellular eosinophilic inflammation. It is likely that around half of all patients with asthma have evidence of T2-high inflammation. Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels, and airway gene expression markers are frequently used biomarkers of T2-high asthma. Individuals with T2-high asthma tend to have several features of increased asthma severity, including reduced lung function and increased rates of asthma exacerbations, and T2-high patients demonstrate distinct pathologic features including increased airway remodeling and alterations in airway mucus production. Several monoclonal antibodies are now available to treat individuals with T2-high asthma and these medications significantly reduce asthma exacerbation rates.
AB - Type 2 (T2) inflammation plays a key role in the pathogenesis of asthma. IL-4, IL-5, and IL-13, along with other inflammatory mediators, lead to increased cellular eosinophilic inflammation. It is likely that around half of all patients with asthma have evidence of T2-high inflammation. Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels, and airway gene expression markers are frequently used biomarkers of T2-high asthma. Individuals with T2-high asthma tend to have several features of increased asthma severity, including reduced lung function and increased rates of asthma exacerbations, and T2-high patients demonstrate distinct pathologic features including increased airway remodeling and alterations in airway mucus production. Several monoclonal antibodies are now available to treat individuals with T2-high asthma and these medications significantly reduce asthma exacerbation rates.
KW - Asthma
KW - Biomarkers in asthma
KW - Monoclonal antibody therapy
KW - Type 2 inflammation
UR - http://www.scopus.com/inward/record.url?scp=85078314308&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2019.11.020
DO - 10.1016/j.jaip.2019.11.020
M3 - Article
C2 - 32037108
AN - SCOPUS:85078314308
SN - 2213-2198
VL - 8
SP - 442
EP - 450
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 2
ER -